Hemogenyx Pharmaceuticals Plc, formerly Silver Falcon Plc, is a biotechnology company. The Company is focused on developing new treatments for blood diseases such as leukaemia, lymphoma and blood marrow failure. Its therapies are designed to provide new treatments in bone marrow/stem cell transplants, improving the success and safety of such treatments. Its products include Conditioning and Cell therapy product. Conditioning product is for CDX bi-specific antibodies, redirects a patient’s own immune cells to eliminate unwanted blood stem cells preparing a patient for bone marrow (also known as haematopoietic stem cell) transplantation. Cell therapy product uses human postnatal hemogenic endothelial cells (HuPHECs) to generate cancer-free, patient-matched blood stem cells after transplant into the patient.